Icon Legend

This session is not on your agenda.

This session is on your agenda. Click again to remove it.

Presentation Icons

ACVIM Resident Research Award Eligible

Additional Fees May Be Required

By Invite Only

Capturing for On Demand

Cardiology Research Abstract Award Eligible

ERC Approved Lecture for ACVIM Residency

Livestream

One Health

Pre-Registration Required

Research Abstract

Specialty Symposium

ACVIM Resident Research Award Winner

Cardiology Research Abstract Award Winner

204 Views

Evaluation ViewAttendees 32

Small Animal Internal Medicine

In Person Only

Panel: Euglycemic Diabetic Ketoacidosis: Discussion on Etiology, Recognition, and Treatment

Thursday, June 19, 2025

10:00 AM - 12:15 PM ET

Location: KICC M103

CE: 2.0 Medical

Sponsored by

Panel Chair(s)

Audrey K. Cook, BVM&S. FRCVS, DACVIM (SAIM), DECVIM-CA, DABVP (Feline) (she/her/hers)

Professor, Small Animal Internal Medicine
Texas A&M College of Veterinary Medicine
College Station, Texas, United States

Panelist(s)

TS

Thomas Schermerhorn, VMD, DACVIM(SAIM) (he/him/his)

Jarvis Professor of Medicine
Kansas State University College of Veterinary Medicine
Manhattan, Kansas, United States
J. Catharine Scott-Moncrieff, Vet MB, MA, MS, DACVIM-SAIM, DECVIM-CA (she/her/hers)

Professor, Department Head
Purdue University
West-Lafayette, Indiana, United States
Jocelyn Mott, DVM, DACVIM (SAIM); FACVIM (feline and canine diabetes)

Associate professor
University of Florida
Gainesville, Florida, United States

Disclosure(s):

Audrey K. Cook, BVM&S. FRCVS, DACVIM (SAIM), DECVIM-CA, DABVP (Feline): No relevant disclosure to display

Thomas Schermerhorn, VMD, DACVIM(SAIM): No relevant disclosure to display

J. Catharine Scott-Moncrieff, Vet MB, MA, MS, DACVIM-SAIM, DECVIM-CA: No relevant disclosure to display

Jocelyn Mott, DVM, DACVIM (SAIM); FACVIM (feline and canine diabetes): No financial relationships to disclose

Presentation Description / Summary: Euglycemic diabetic ketoacidosis (EDKA)is an unfamiliar disorder within veterinary medicine, but is now a concern following the introduction of SGLT2 inhibitors as stand-alone therapy for cats with diabetes mellitus. Many specialists are anxious about how to prevent, diagnose and manage this condition. In this panel discussion, a group of internists with interest in SGLT2 inhibitors will answer questions regarding the identification of patients at risk of EDKA, current understanding regarding the pathophysiology of EDKA, and appropriate treatment strategies. Audience members will be encouraged to participate and share their own concerns and experiences with this condition.

Learner Outcomes: 1. Understand the physiology behind euglycemic diabetic ketoacidosis 2. Identify patients at risk of euglycemic diabetic ketoacidosis 3. Create appropriate treatment protocols for cats with euglycemic ketoacidosis

Learning Objectives:

Identify cats at risk of euglycemic diabetic ketoacidosis and create appropriate monitoring plans
Understand the nuances of the pathogenesis of euglycemic diabetic ketoacidosis in cats treated with SGLT2 inhibitors
Create effective treatment plans for cats with euglycemic ketoacidosis